How innovative technologies like AI and gene editing are advancing rare disease drug discovery and development.

Southern California residents are noticing new license plate readers that appear to be operated by the Border Patrol.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen ...

Azitra, Inc. ("Azitra") , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended ...

Southern California residents are noticing new license plate readers that appear to be operated by the Border Patrol. Some ...

An independent 2026 overview of Lottery Unlocked's Quantum+ Algorithm claims, what the company states about its AI lottery ...

GMO's Equity Dislocation Strategy returned 13.4% net in 2025, capitalising on wide valuation spreads. Read the full analysis ...

The American Hospital Association provides comment on the “Health Data, Technology and Interoperability: ASTP/ONC Deregulatory Actions to Unleash Prosperity” (HTI-5) proposed rule.

Helfert: What’s changed is the market’s growing concern that the key AI risk isn’t near-term earnings destruction, it’s acceleration of the fade rate—the speed at which a company’s excess profits ...

Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company antici ...

An independent fact-checked overview covering Lotto Master Key company claims, AI lottery analysis verification, documented winner comparisons, ClickBank refund terms, pricing breakdown, and what ever ...